Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227184 | 0.89 | SMN1; SMN2 (0.60) | TSHRSMN1; SMN2P4HTMFFAR1TBXAS1 | |
| SCHEMBL7209273 | 0.89 | SMN1; SMN2 (0.60) | TSHRSMN1; SMN2P4HTMFFAR1TBXAS1 | |
| SCHEMBL12295789 | 0.85 | SMN1; SMN2 (0.55) | TSHRSMN1; SMN2P4HTMFFAR1FFAR4 | |
| SCHEMBL5395383 | 0.84 | TSHR (0.54) | TSHRSMN1; SMN2P4HTMFFAR1FFAR4 | |
| SCHEMBL5709790 | 0.84 | TSHR (0.54) | TSHRSMN1; SMN2P4HTMLMNAL3MBTL1 | |
| SCHEMBL15121007 | 0.82 | TSHR (0.53) | TSHRSMN1; SMN2P4HTMLMNAL3MBTL1 | |
| SCHEMBL7962602 | 0.81 | P4HTM (0.68) | SMN1; SMN2P4HTMFFAR1FFAR4TBXAS1 | |
| SCHEMBL575044 | 0.81 | GABRP (0.61) | TSHRSMN1; SMN2P4HTMLMNA | |
| SCHEMBL4734773 | 0.81 | TSHR (0.51) | TSHRSMN1; SMN2P4HTMLMNA | |
| SCHEMBL12197963 | 0.81 | TSHR (0.51) | TSHRSMN1; SMN2P4HTMFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0070185-B1 | PREPARATION OF LOWER ALKYL 2-FORMYL-3-(6-METHYL-3-PYRIDINYL)-PROPIONATES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-10 | — | — | EP | claimed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-9409900-B2 | Compound for increasing kinase active and application thereof | FUJIAN HAIXI PHARMACEUTICALS, INC. (CN) | 2016-08-09 | — | — | US | disclosed |
| EP-2274307-B1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9034869-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999977-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8546381-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130225587-A1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | ZHEJIANG BETA PHARMA INCORPORATION (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-0206294-B1 | ALKYL ESTERS OF 3-HYDROXY-3-(2-METHYL-5-PYRIDYL)-PROPIONIC ACID | LONZA AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| US-4778796-A | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0210782-A2 | Pyridine compounds, process for the preparation thereof and pharmaceutical composition containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-02-04 | — | — | EP | disclosed |
| EP-0206294-A1 | Alkyl esters of 3-hydroxy-3-(2-methyl-5-pyridyl)-propionic acid | LONZA AG (CH) | 1986-12-30 | — | — | EP | disclosed |
| EP-0070185-B1 | PREPARATION OF LOWER ALKYL 2-FORMYL-3-(6-METHYL-3-PYRIDINYL)-PROPIONATES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-10 | — | — | EP | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225587-A1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | MAP3K7, MAP3K1, MAP3K6 | TSHR 1956/4885SMN1; SMN2 4291/4885P4HTM 2770/4885 |
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | TSHR 961/4885SMN1; SMN2 3057/4885P4HTM 892/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | TSHR 1109/4885SMN1; SMN2 4482/4885P4HTM 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.